Agilent Technologies (A)

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,² Agilent Technologies...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 144 - Report of proposed sale of securities

Form SD - Specialized disclosure report

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories...

Form 8-K - Current report

Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum...

Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality

New 8890B and 8860B gas chromatographs integrate intelligent monitoring and remote diagnostics Agilent Technologies Inc. (NYSE: A) today...

Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis

Next-generation ICP-MS/MS delivers faster measurements, simplified workflows, and easier access to advanced...

Form 4 - Statement of changes in beneficial ownership of securities